Literature DB >> 33507067

Avoiding Drug Resistance in HIV Reverse Transcriptase.

Maria E Cilento1,2, Karen A Kirby1,2, Stefan G Sarafianos1,2.   

Abstract

HIV reverse transcriptase (RT) is an enzyme that plays a major role in the replication cycle of HIV and has been a key target of anti-HIV drug development efforts. Because of the high genetic diversity of the virus, mutations in RT can impart resistance to various RT inhibitors. As the prevalence of drug resistance mutations is on the rise, it is necessary to design strategies that will lead to drugs less susceptible to resistance. Here we provide an in-depth review of HIV reverse transcriptase, current RT inhibitors, novel RT inhibitors, and mechanisms of drug resistance. We also present novel strategies that can be useful to overcome RT's ability to escape therapies through drug resistance. While resistance may not be completely avoidable, designing drugs based on the strategies and principles discussed in this review could decrease the prevalence of drug resistance.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33507067      PMCID: PMC8149104          DOI: 10.1021/acs.chemrev.0c00967

Source DB:  PubMed          Journal:  Chem Rev        ISSN: 0009-2665            Impact factor:   60.622


  301 in total

1.  Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel.

Authors:  S A Wegner; S K Brodine; J R Mascola; S A Tasker; R A Shaffer; M J Starkey; A Barile; G J Martin; N Aronson; W W Emmons; K Stephan; S Bloor; J Vingerhoets; K Hertogs; B Larder
Journal:  AIDS       Date:  2000-05-26       Impact factor: 4.177

2.  Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study.

Authors:  S Duwe; M Brunn; D Altmann; O Hamouda; B Schmidt; H Walter; G Pauli; C Kücherer
Journal:  J Acquir Immune Defic Syndr       Date:  2001-03-01       Impact factor: 3.731

Review 3.  Rates of transmission of antiretroviral drug resistant strains of HIV-1.

Authors:  Palanee Ammaranond; Philip Cunningham; Robert Oelrichs; Kazuo Suzuki; Claire Harris; Leakhena Leas; Andrew Grulich; David A Cooper; Anthony D Kelleher
Journal:  J Clin Virol       Date:  2003-02       Impact factor: 3.168

4.  Adherence, resistance, and timing: current issues in the use of new therapies.

Authors:  Paul Volberding
Journal:  AIDS Read       Date:  2002-08

5.  Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine in vitro and in vivo.

Authors:  Michael Murphey-Corb; Premeela Rajakumar; Heather Michael; Julia Nyaundi; Peter J Didier; Aaron B Reeve; Hiroaki Mitsuya; Stefan G Sarafianos; Michael A Parniak
Journal:  Antimicrob Agents Chemother       Date:  2012-06-19       Impact factor: 5.191

6.  Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.

Authors:  K Theys; R J Camacho; P Gomes; A M Vandamme; S Y Rhee
Journal:  Clin Microbiol Infect       Date:  2015-02-19       Impact factor: 8.067

7.  Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance.

Authors:  A Mas; M Parera; C Briones; V Soriano; M A Martínez; E Domingo; L Menéndez-Arias
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

8.  Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

Authors:  T Imamichi; S C Berg; H Imamichi; J C Lopez; J A Metcalf; J Falloon; H C Lane
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

9.  Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir.

Authors:  Hironori Hayashi; Nobutoki Takamune; Takashi Nirasawa; Manabu Aoki; Yoshihiko Morishita; Debananda Das; Yasuhiro Koh; Arun K Ghosh; Shogo Misumi; Hiroaki Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

10.  Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.

Authors:  Paul L Boyer; Stefan G Sarafianos; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more
  7 in total

1.  Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.

Authors:  Maria E Cilento; Aaron B Reeve; Eleftherios Michailidis; Tatiana V Ilina; Eva Nagy; Hiroaki Mitsuya; Michael A Parniak; Philip R Tedbury; Stefan G Sarafianos
Journal:  Antimicrob Agents Chemother       Date:  2021-09-13       Impact factor: 5.191

Review 2.  Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies.

Authors:  Abhimanyu K Singh; Kalyan Das
Journal:  Viruses       Date:  2022-05-11       Impact factor: 5.818

Review 3.  Why the HIV Reservoir Never Runs Dry: Clonal Expansion and the Characteristics of HIV-Infected Cells Challenge Strategies to Cure and Control HIV Infection.

Authors:  Chuen-Yen Lau; Matthew A Adan; Frank Maldarelli
Journal:  Viruses       Date:  2021-12-14       Impact factor: 5.048

Review 4.  Recent advances in carbon quantum dots for virus detection, as well as inhibition and treatment of viral infection.

Authors:  Yuxiang Xue; Chenchen Liu; Gavin Andrews; Jinyan Wang; Yi Ge
Journal:  Nano Converg       Date:  2022-04-02

5.  Which 'imperfect vaccines' encourage the evolution of higher virulence?

Authors:  James J Bull; Rustom Antia
Journal:  Evol Med Public Health       Date:  2022-04-26

Review 6.  Approved HIV reverse transcriptase inhibitors in the past decade.

Authors:  Guangdi Li; Yali Wang; Erik De Clercq
Journal:  Acta Pharm Sin B       Date:  2021-11-16       Impact factor: 14.903

7.  Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine.

Authors:  Abhimanyu K Singh; Brent De Wijngaert; Marc Bijnens; Kris Uyttersprot; Hoai Nguyen; Sergio E Martinez; Dominique Schols; Piet Herdewijn; Christophe Pannecouque; Eddy Arnold; Kalyan Das
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-19       Impact factor: 12.779

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.